Shuigen Zhou1, Jiandong Wang, Zhengyu Zhang. 1. Department of Urology, Jinling Hospital, Nanjing University School of Medicine, No. 305, Zhongshandong Road, Nanjing, 210002, Jiangsu, People's Republic of China.
Abstract
BACKGROUND: Long noncoding RNAs (lncRNAs) are pervasively transcribed in the genome and are emerging as new players in tumorigenesis. METHODS: An electronic search of all relevant publications in peer-reviewed journals before April 2014 was performed on PubMed, Google scholar databases. The keywords of long-coding RNAs, lncRNAs, kidney tumor, renal cancers were used for searching. RESULTS: The lncRNA biology was introduced into cancer biology from contemporary research, and the regulatory mechanisms of lncRNAs was highlighted at transcriptional, post-transcriptional and epigenetic levels. The kidney cancer-associated onco-lncRNAs (e.g., KCQN1OT1, MALAT-1 and HOTAIT) and tumor suppressive lncRNAs (e.g., H19, GAS5 and MEG3) were summarized and their possible regulatory network was depicted in a comprehensive diagram. CONCLUSION: LncRNAs are deregulated in various cancers including kidney cancer, demonstrating both oncogenic and tumor suppressive roles, thus suggesting their aberrant expression may be a substantial contributor in cancer development. LncRNAs could serve as potential diagnostics biomarkers and/or therapeutic targets.
BACKGROUND: Long noncoding RNAs (lncRNAs) are pervasively transcribed in the genome and are emerging as new players in tumorigenesis. METHODS: An electronic search of all relevant publications in peer-reviewed journals before April 2014 was performed on PubMed, Google scholar databases. The keywords of long-coding RNAs, lncRNAs, kidney tumor, renal cancers were used for searching. RESULTS: The lncRNA biology was introduced into cancer biology from contemporary research, and the regulatory mechanisms of lncRNAs was highlighted at transcriptional, post-transcriptional and epigenetic levels. The kidney cancer-associated onco-lncRNAs (e.g., KCQN1OT1, MALAT-1 and HOTAIT) and tumor suppressive lncRNAs (e.g., H19, GAS5 and MEG3) were summarized and their possible regulatory network was depicted in a comprehensive diagram. CONCLUSION: LncRNAs are deregulated in various cancers including kidney cancer, demonstrating both oncogenic and tumor suppressive roles, thus suggesting their aberrant expression may be a substantial contributor in cancer development. LncRNAs could serve as potential diagnostics biomarkers and/or therapeutic targets.
Authors: Moran N Cabili; Cole Trapnell; Loyal Goff; Magdalena Koziol; Barbara Tazon-Vega; Aviv Regev; John L Rinn Journal: Genes Dev Date: 2011-09-02 Impact factor: 11.361
Authors: Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal Journal: Gastroenterology Date: 2006-08-14 Impact factor: 22.682
Authors: Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell Journal: Mol Cancer Res Date: 2012-05-25 Impact factor: 5.852
Authors: Glauber Costa Brito; Angela A Fachel; Andre Luiz Vettore; Giselle M Vignal; Etel R P Gimba; Franz S Campos; Marcello A Barcinski; Sergio Verjovski-Almeida; Eduardo M Reis Journal: Mol Carcinog Date: 2008-10 Impact factor: 4.784
Authors: Thomas Derrien; Rory Johnson; Giovanni Bussotti; Andrea Tanzer; Sarah Djebali; Hagen Tilgner; Gregory Guernec; David Martin; Angelika Merkel; David G Knowles; Julien Lagarde; Lavanya Veeravalli; Xiaoan Ruan; Yijun Ruan; Timo Lassmann; Piero Carninci; James B Brown; Leonard Lipovich; Jose M Gonzalez; Mark Thomas; Carrie A Davis; Ramin Shiekhattar; Thomas R Gingeras; Tim J Hubbard; Cedric Notredame; Jennifer Harrow; Roderic Guigó Journal: Genome Res Date: 2012-09 Impact factor: 9.043